Aliskiren


Article Author:
Tibb Jacobs


Article Editor:
Jamie Terrell


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Kyle Blair
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Abbey Smiley
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Daniyal Ameen
Altif Muneeb
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes
Komal Shaheen
Sandeep Sekhon


Updated:
10/12/2019 3:17:02 PM

Indications

Aliskiren is FDA approved to treat hypertension in adults and children 6 years and older. It may be used as monotherapy or in combination with other antihypertensive agents. It is currently available as a combination product with hydrochlorothiazide as well as with amlodipine and hydrochlorothiazide.

Aliskiren first received approval in 2007 after demonstrating its antihypertensive effects in six randomized, double-blind, placebo-controlled trials. All patients included had mild to moderate hypertension. Most patients demonstrated a blood pressure-lowering effect within two weeks of treatment. These studies demonstrated a mean reduction in systolic blood pressure of 2.9 to 10 mmHg and a mean reduction in diastolic blood pressure of 3.3 to 8.6 mmHg.[1][2][3]

In November of 2017, the American College of Cardiology (ACC) and the American Heart Association (AHA) released updated treatment guidelines for patients with high blood pressure. According to the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, most patients will have a blood pressure goal of less than 130/80 mmHg. This guideline is a significant change from the 2014 JNC 8 Guidelines (Evidence-based guideline for the management of high blood pressure in adults: a report from panel members appointed to the Eighth Joint National Committee JNC8). The JNC 8 guidelines recommended a blood pressure goal of 140/90 mmHg for most patients and an even higher blood pressure goal for elderly patients. For patients over the age of 60, the JNC 8 guideline recommended a blood pressure goal of less than 150/90 mmHg.  

In addition to the new lower blood pressure goals, the ACC/AHA guidelines have a strong focus on decreasing the risk of cardiovascular disease. Their current recommendation is that patients with elevated blood pressure should receive treatment with medication to reduce cardiovascular risk by lowering blood pressure. However, aliskiren does not currently have outcome data available demonstrating cardiovascular disease (CVD) risk reduction with its use. The ACC/AHA guidelines emphasize the importance of blood pressure-lowering over drug selection, but initial recommendations for most patients currently include calcium channel blockers, thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin-receptor blockers (ARB) because of their evidence of CVD risk reduction.

There is also no outcome data for using aliskiren in patients with diabetes and nephropathy, patients with coronary artery disease, or post-MI patients. The ATMOSPHERE study found aliskiren not to be inferior to enalapril in congestive heart failure patients in the primary composite endpoint of CV death or heart failure hospitalization. Aliskiren does not have an indication for these disease states and would probably not be a substitute for ACEIs or ARBs for these patients.

At this time, aliskiren remains a medication that would be most appropriate for use as an add-on therapy for patients already managed with one or more medications that have demonstrated the ability to decrease cardiovascular risk.[4][5]

Mechanism of Action

Aliskiren is active in the renin-angiotensin-aldosterone system (RAAS). Renin gets secreted by the kidney based on changes in blood volume and renal perfusion. Renin is responsible for the conversion of angiotensinogen to angiotensin I. Angiotensin I is converted to angiotensin II by the angiotensin-converting enzyme (ACE). Angiotensin II binds to the AT1 receptor and works as a vasoconstrictor, causing the release of catecholamines and promoting aldosterone secretion and sodium reabsorption. These effects together act to increase blood pressure. Angiotensin II also can inhibit renin release, causing negative feedback to the renin-angiotensin-aldosterone system. 

Aliskiren acts as a renin inhibitor, which blocks the conversion of angiotensinogen to angiotensin I. This effect subsequently decreases the formation of angiotensin II. Angiotensin II acts on the AT1 receptor, which is responsible for vasoconstriction, aldosterone secretion, and catecholamine release. Hence blood pressure is decreased by decreasing the amount of angiotensin II to reach the AT1 receptor, thereby causing a decrease in vasoconstriction, aldosterone secretion, and catecholamine release. Any agent that works to inhibit the RAAS can suppress the negative feedback loop.

Administration

Aliskiren is available as 150 mg or 300 mg tablets. Patients usually initiate therapy on 150 mg daily and may be increased to 300 mg daily if necessary. Doses over 300 mg daily did not demonstrate any additional blood pressure lowering but did show an increased rate of diarrhea. Aliskiren is also available as oral pellets for patients who cannot swallow tablets. The pellets are available as a 37.5 mg capsule.

Aliskiren administration is oral. It should be taken daily at the same time. Patients may take aliskiren with or without a meal, but the recommendation is for consistent administration with regard to meals. High-fat meals can decrease the absorption of aliskiren.

Aliskiren is also available in combination with hydrochlorothiazide in multiple strengths: 150-12.5 mg, 150-25 mg, 300-12.5 mg, and 300-25 mg.

It is also available in combination with amlodipine and hydrochlorothiazide: 150-5-12.5 mg, 300-5-12.5 mg, 300-5-25 mg, 300-10-12.5 mg, and 300-10-25 mg.

Adverse Effects

According to the package insert, the primary adverse effect of aliskiren is diarrhea, with 2.3% of patients experiencing it. Other common adverse effects include a cough, skin rash, headaches, and dizziness.

Clinical lab findings seen in clinical trials include: increased blood urea nitrogen or serum creatinine, small decreases in hemoglobin and hematocrit, increases in serum potassium, increased serum uric acid, and increased creatine kinase.

Serious adverse reactions reported in clinical trials include fetal toxicity, anaphylactic reactions, head and neck angioedema, and hypotension.  

Contraindications

According to the manufacturer, aliskiren is contraindicated in patients with a known hypersensitivity to any component, in pediatric patients less than two years, and in patients with diabetes mellitus who are taking an ACE inhibitor or an angiotensin receptor blocker.

Patients should not use aliskiren in pregnancy or if they are taking an ARB or ACEI. Caution is necessary for patients who have volume depletion.

Monitoring

Medical staff should observe patients taking aliskiren for hyperkalemia and impaired renal function. Serum potassium requires periodic monitoring. Patients at risk include those with renal insufficiency, diabetes, combination use with ARBs or ACEs, and patients using potassium supplements or potassium-sparing diuretics. Renal function also should be monitored periodically. Individual patients will be at higher risk of developing acute renal failure while taking aliskiren. These patients include those taking ARBs, ACEIs, non-steroidal anti-inflammatory drugs (NSAIDs), as well as patients with renal artery stenosis, severe heart failure, post-myocardial infarction, or, are volume depleted.[6][7]

Toxicity

There is limited data regarding overdose in humans. Most likely, patients would present with hypotension. If this occurs, supportive treatment would be appropriate.

Enhancing Healthcare Team Outcomes

Healthcare workers, including nurse practitioners who prescribe aliskiren for hypertension in adults, should know the contraindications and precautions. Patients taking aliskiren requires monitoring for hyperkalemia and impaired renal function. Serum potassium also requires periodic observation. Patients at risk include those with renal insufficiency, diabetes, combination use with ARBs or ACEs, and patients using potassium supplements or potassium-sparing diuretics. Renal function is also something clinicians should watch. Individual patients will be at higher risk of developing acute renal failure while taking aliskiren. These patients include those taking ARBs, ACEIs, non-steroidal anti-inflammatory drugs (NSAIDs), as well as patients with renal artery stenosis, severe heart failure, post-myocardial infarction, or, are volume depleted.

ALiskiren therapy, as part of a patient's overall hypertensive control regimen, requires an interprofessional healthcare team. When initiating aliskiren, the clinician should consult a pharmacist, who can look over the entire medication regimen and assist with deciding the appropriateness of adding aliskiren, and what other changes might be necessary for the patient's regimen. Nursing can provide administration counseling, monitor the patient as described above, and assess compliance. If the nurse or pharmacist note any issues, they should be able to communicate these to the prescriber promptly. With this type of interprofessional team coordination, aliskiren therapy can achieve optimal outcomes with minimal adverse events. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Aliskiren - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following drugs is a renin inhibitor?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient has been prescribed aliskiren and lab results show that the patient is hypovolemic. What should be done?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is the brand name for aliskiren?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient comes into the pharmacy with a prescription for Tekturna. Upon reviewing his medication profile you find that the patient has diabetes mellitus and is currently taking Lotensin for hypertension. What should you do about this prescription?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following patients would be most appropriate for the addition of aliskiren for the treatment of hypertension?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Aliskiren - References

References

Łukawski K,Raszewski G,Czuczwar SJ, Effect of aliskiren, a direct renin inhibitor, on the protective action of antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice. Fundamental     [PubMed]
Yamashita S,Biswas KB,Nabi AHMN,Nakagawa T,Suzuki F,Ebihara A, Aliskiren reduces the release of soluble (pro)renin receptor from human umbilical vein endothelial cells. Biomedical reports. 2018 Sep;     [PubMed]
Nakano D,Nishiyama A, A novel role of renin inhibitor in the complement cascade. Kidney international. 2018 Oct;     [PubMed]
Yandrapalli S,Jolly G,Biswas M,Rochlani Y,Harikrishnan P,Aronow WS,Lanier GM, Newer hormonal pharmacotherapies for heart failure. Expert review of endocrinology     [PubMed]
Simeoni M,Nicotera R,Pelagi E,Libri E,Comi N,Fuiano G, Successful use of Aliskiren in a case of IgA- mesangial glomerulonephritis unresponsive to conventional therapies. Reviews on recent clinical trials. 2018 Jul 25;     [PubMed]
Békássy ZD,Kristoffersson AC,Rebetz J,Tati R,Olin AI,Karpman D, Aliskiren inhibits renin-mediated complement activation. Kidney international. 2018 Oct;     [PubMed]
Pawloski PL,Moreira CG,Horinouchi CDS,Fernandes D,Olchanheski LR Júnior,Machado W,Cabrini DA,Dietrich M,Paludo K,Otuki MF, Aliskiren: Preclinical evidence for the treatment of hyperproliferative skin disorders. Biomedicine     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.